Ocular Therapeutix Inc. - notizie pubblicate 213 - letture 2.913
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Reports First Quarter 2024 Results
Recent leadership appointments put ocular on track to become a leader in retinal care site activation and patient enrollment for axpaxli™ sol-1 phase 3 wet amd trial progressing ...
OCULAR THERAPEUTIX INC.
Additional Proxy Soliciting Materials - Form DEFA14A
united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bedford, mass., may 06, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) ("ocular"), a biopharmaceutical company committed to enhancing people's vision and ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
Bedford, mass., may 06, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul, "ocular", the "company"), a biopharmaceutical company committed to enhan ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
2024 ois retina and arvo meetings are being held in seattle, washington bedford, mass., may 03, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul, "ocular", ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
First quarter 2024 financial results to be reported on tuesday, may 7, 2024 investor day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular c ...
OCULAR THERAPEUTIX INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer ocular therapeutix inc. published this ...
OCULAR THERAPEUTIX INC.
Proxy Statement - Form DEF 14A
Table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1 ...
OCULAR THERAPEUTIX INC.
Preliminary Proxy Statement - Form PRE 14A
Table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1 ...
OCULAR THERAPEUTIX INC.
Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K
Amendment no. 3 to 2019 inducement stock incentive plan ocular therapeutix, inc's 2019 inducement stock incentive plan (the "plan"), pursuant to section 11(d) thereof, is ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
46.2% of patients demonstrated a 1- or 2-step improvement in the diabetic retinopathy severity scale (drss) at 40 weeks in the axpaxli arm, compared to 0% in the control arm no pat ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Nadia k. waheed, md, mph, appointed chief medical officer; peter k. kaiser, md, to become chief development officer; andrea gibson, phd, named vice president, medical collaboration ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Bedford, mass., april 15, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) ("ocular"), a biopharmaceutical company committed to enhancing people's vision a ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Bedford, mass., april 09, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) ("ocular"), a biopharmaceutical company committed to enhancing people's vision a ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Phase 2 data highlight consistent and sustained reductions in intraocular pressure (iop), statistically significant (p<0.0001) through six months, with clinically meaningful red ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti